Literature DB >> 26419676

Transungual permeation: current insights.

Ronak S Bhuptani1, Ketaki M Deshpande1, Vandana B Patravale2.   

Abstract

Nail disorders are beyond cosmetic concern; besides discomfort in the performance of daily chores, they disturb patients psychologically and affect their quality of life. Fungal nail infection (onychomycosis) is the most prevalent nail-related disorder affecting a major population worldwide. Overcoming the impenetrable nail barrier is the toughest challenge for the development of efficacious topical ungual formulation. Sophisticated techniques such as iontophoresis and photodynamic therapy have been proven to improve transungual permeation. This article provides an updated and concise discussion regarding the conventional approach and upcoming novel approaches focused to alter the nail barrier. A comprehensive description regarding preformulation screening techniques for the identification of potential ungual enhancers is also described in this review while highlighting the current pitfalls for the development of ungual delivery.

Entities:  

Keywords:  Nail hydration; Onychomycosis; Transungual; Ungual permeation; Ungual screening techniques

Mesh:

Substances:

Year:  2016        PMID: 26419676     DOI: 10.1007/s13346-015-0259-6

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  64 in total

1.  Ultrasound-mediated nail drug delivery system.

Authors:  Danielle Abadi; Vesna Zderic
Journal:  J Ultrasound Med       Date:  2011-12       Impact factor: 2.153

Review 2.  Evaluation of nail abnormalities.

Authors:  Amber S Tully; Kathryn P Trayes; James S Studdiford
Journal:  Am Fam Physician       Date:  2012-04-15       Impact factor: 3.292

3.  Treatment of onychomycosis with nail avulsion and topical ketoconazole.

Authors:  D F Hettinger; M S Valinsky
Journal:  J Am Podiatr Med Assoc       Date:  1991-01

4.  Permeability characteristics of the human nail plate.

Authors:  K A Walters; G L Flynn
Journal:  Int J Cosmet Sci       Date:  1983-12       Impact factor: 2.970

5.  Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.

Authors:  Tsuyoshi Shimamura; Nobuo Kubota; Saori Nagasaka; Taku Suzuki; Hideki Mukai; Kazutoshi Shibuya
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

6.  A study on the effect of inorganic salts in transungual drug delivery of terbinafine.

Authors:  Anroop B Nair; Srinivasa M Sammeta; Siva Ram K Vaka; S Narasimha Murthy
Journal:  J Pharm Pharmacol       Date:  2009-04       Impact factor: 3.765

7.  Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study.

Authors:  B Amichai; B Nitzan; R Mosckovitz; A Shemer
Journal:  Br J Dermatol       Date:  2009-07-20       Impact factor: 9.302

8.  Medical devices for the treatment of onychomycosis.

Authors:  Aditya K Gupta; Fiona C Simpson
Journal:  Dermatol Ther       Date:  2012 Nov-Dec       Impact factor: 2.851

9.  Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.

Authors:  Farhaan Hafeez; Xiaoying Hui; Marc Selner; Bert Rosenthal; Howard Maibach
Journal:  Drug Dev Ind Pharm       Date:  2013-04-19       Impact factor: 3.225

10.  Iontophoretically enhanced ciclopirox delivery into and across human nail plate.

Authors:  Jinsong Hao; Kelly A Smith; S Kevin Li
Journal:  J Pharm Sci       Date:  2009-10       Impact factor: 3.534

View more
  2 in total

Review 1.  Mechanistic Insights of Formulation Approaches for the Treatment of Nail Infection: Conventional and Novel Drug Delivery Approaches.

Authors:  Agrawal Vikas; Patel Rashmin; Patel Mrunali; Rahul B Chavan; Thanki Kaushik
Journal:  AAPS PharmSciTech       Date:  2020-01-14       Impact factor: 3.246

2.  Effect on Nail Structure and Transungual Permeability of the Ethanol and Poloxamer Ratio from Cyclodextrin-Soluble Polypseudorotaxanes Based Nail Lacquer.

Authors:  Elena Cutrín-Gómez; Soledad Anguiano-Igea; M Begoña Delgado-Charro; José Luis Gómez-Amoza; Francisco J Otero-Espinar
Journal:  Pharmaceutics       Date:  2018-09-11       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.